RXRX Insider Trading Activity and SEC Form 4 Filings
RXRX insider trading summary
Over the past 12 months, insiders at Recursion Pharmaceuticals, Inc. (RXRX) reported 29 sales worth $6.5M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $6.5M.
Latest RXRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 3, 2026 | Blake Borgeson | Director | Sell | $155K (40,000 @ $3.88) |
| Oct 6, 2026 | Blake Borgeson | Director | Sell | $242K (50,000 @ $4.84) |
| Oct 6, 2026 | Robert Hershberg | Director | Sell | $125K (25,000 @ $5.00) |
| Sep 1, 2026 | Blake Borgeson | Director | Sell | $100K (30,000 @ $3.34) |
| Jul 7, 2026 | Blake Borgeson | Director | Sell | $159K (40,000 @ $3.96) |
| Jun 18, 2026 | Namandje Bumpus | Director | Sell | $13K (3,963 @ $3.18) |
| Jun 3, 2026 | Namandje Bumpus | Director | Sell | $16K (4,386 @ $3.54) |
| Jun 2, 2026 | Blake Borgeson | Director | Sell | $110K (30,000 @ $3.68) |
| May 22, 2026 | Christopher Gibson | Director | Sell | $123K (40,000 @ $3.08) |
| May 7, 2026 | Christopher Gibson | Director | Sell | $135K (40,000 @ $3.37) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.